Guardant Health Inc - Company Profile
Powered by 
All the sales intelligence you need on Guardant Health Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Guardant Health Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Guardant Health Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Guardant Health Inc (Guardant Health) is a precision oncology company that develops treatments for cancer through blood and tissue tests. The company offers products such as Shield is a blood test screen for colon cancer; Guardant360 Liquid is a liquid test for cancer; Guardant360 CDx test for lung cancer, breast cancer, colorectal cancer and prostate cancer; Guardant360 Tissue is a multiomic test for solid tumors. Its proprietory Guardant Infinity technology platform delivers multiomic insights with genomic, epigenomic, and RNA-based fusion data that are scalable from research to the clinic. The company operates in Americas, Europe and Asia, Middle East, Africa (AMEA) regions. Guardant Health is headquartered in Pao Alto, California, the US.
Headquarters
United States of America
Address
3100 Hanover Street, Palo Alto, California, 94304
Website
guardanthealth.com
Telephone
1 855 6988887
No of Employees
2,490
Industry
Medical Equipment
Ticker Symbol & Exchange
GH (NASD)
Revenue (2024)
$982.0M
32.9%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
4.6%
(2024 vs 2023)
Market Cap*
$19.6B
Net Profit Margin (2024)
XYZ
28.2%
(2024 vs 2023)
* As of and is in US$
Guardant Health Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Shield: colon cancer | Guardant Infinity |
| Guardant360 Liquid:Lung Cancer, Breast Cancer, Colorectal Cancer and Prostate Cancer | Guardant Complete |
| Guardant360 CDx: Lung Cancer, Breast Cancer, Colorectal Cancer and Prostate Cancer | Shield |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | New Products/Services | In March, the company introduced Shield Across America, a coast-to-coast mobile screening tour bringing Shield. |
| 2026 | Contracts/Agreements | In March, the company formed a partnership with Verana Health to merge clinicogenomic test results with therapeutic-grade EHR datasets to speed up biopharma discovery and refine patient care. |
| 2026 | Contracts/Agreements | In March, the company partnered with Manulife to launch the Shield multi-cancer detection test in Asia, enhancing access to early cancer detection. |
Competitor Comparison
| Key Parameters | Guardant Health Inc | Quest Diagnostics Inc | Exact Sciences Corp | Tempus AI Inc | Caris Life Sciences Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Palo Alto | Secaucus | Madison | Chicago | Irving |
| State/Province | California | New Jersey | Wisconsin | Illinois | Texas |
| No. of Employees | 2,490 | 46,000 | 7,200 | 3,800 | 1,846 |
| Entity Type | Public | Public | Private | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Helmy Eltoukhy | Chairman; Co-Chief Executive Officer | Executive Board | 2013 | 47 |
| AmirAli Talasaz | Co-Chief Executive Officer; Director | Executive Board | 2013 | 46 |
| Michael Bell | Chief Financial Officer | Senior Management | 2021 | 57 |
| Kumud Kalia | Chief Information Officer | Senior Management | 2021 | 60 |
| Darya Chudova | Chief Technology Officer | Senior Management | 2023 | 52 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer